Effect of High Intensity Interval Training on Matrix Metalloproteinases in Women with Breast Cancer Receiving Anthracycline-Based Chemotherapy

被引:32
|
作者
Lee, Kyuwan [1 ]
Kang, Irene [2 ]
Mack, Wendy J. [3 ]
Mortimer, Joanne [4 ]
Sattler, Fred [2 ]
Salem, George [5 ]
Dieli-Conwright, Christina M. [6 ]
机构
[1] Univ Southern Calif USC, Childrens Hosp Los Angeles, Keck Sch Med, Div Cardiol, Los Angeles, CA 90089 USA
[2] USC, Dept Med, Keck Sch Med, Los Angeles, CA 90089 USA
[3] USC, Dept Prevent Med, Keck Sch Med, Los Angeles, CA 90089 USA
[4] City Hope Comprehens Canc Ctr, Div Med Oncol & Expt Therapeut, Duarte, CA 91010 USA
[5] USC, Div Biokinesiol & Phys Therapy, Ostrow Sch Dent, Los Angeles, CA 90089 USA
[6] Harvard Med Sch, Dana Farber Canc Inst, Div Populat Sci, Boston, MA 02215 USA
基金
美国国家卫生研究院;
关键词
OXIDATIVE STRESS; ENDOTHELIAL FUNCTION; PHYSICAL-EXERCISE; TNF-ALPHA; T TEST; MMP-9; IL-6; MATRIX-METALLOPROTEINASE-9; EXPRESSION; DISEASE;
D O I
10.1038/s41598-020-61927-x
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
Anthracycline chemotherapy is commonly used to treat breast cancer yet may increase the level of matrix metalloproteinases (MMP) -2 and -9, which increase the risk of atherosclerosis. While exercise has been shown to reduce the level of MMP in patients with diabetes, high intensity interval training (HIIT) has not been utilized to improve level of MMP in women with breast cancer receiving anthracycline chemotherapy. Thirty women were randomized to either 8-week HIIT or control (CON) group. The CON group was offered the HIIT intervention after 8 weeks. MMP-1, -2 -7, -9, tissue inhibitor of MMP (TIMP) -1, and-2 were measured at baseline and post-intervention. Repeated measures ANCOVA and paired t-test were performed to assess changes in MMP and TIMP. Post-intervention, no significant between-group differences were observed for MMP and TIMP. However, within-group decrease in MMP-9 was observed in the HIIT group [104.3(51.9) to 65.2(69.1); P = 0.01]. MMP-9 in the CON group was not significantly changed [115.5(47.2) to 90.4(67.9);]. MMP-2 significantly increased in both the HIIT group [76.6(11.2) to 83.2(13.1); P = 0.007) and the CON group [69.0(8.9) to 77.6(11.1) P = 0.003). It is unclear whether an 8-week HIIT intervention influences MMP-9 in breast cancer patients undergoing anthracycline chemotherapy. Additional investigations are required to understand the exercise-induced changes in MMP-2 and -9 in women undergoing anthracycline chemotherapy.
引用
收藏
页数:7
相关论文
共 50 条
  • [41] Prediction of trastuzumab-induced cardiotoxicity in breast cancer patients receiving anthracycline-based chemotherapy: methodological issues
    Naderi, Mehdi
    Sabour, Siamak
    JOURNAL OF ECHOCARDIOGRAPHY, 2019, 17 (02) : 112 - 113
  • [42] Prediction of trastuzumab-induced cardiotoxicity in breast cancer patients receiving anthracycline-based chemotherapy: methodological issues
    Mehdi Naderi
    Siamak Sabour
    Journal of Echocardiography, 2019, 17 : 112 - 113
  • [43] Effectivity of Bromocriptine Administration Towards Prolactin Positive Breast Cancer Receiving Anthracycline-Based Chemotherapy: A Literature Review
    Permana, Muhammad Yadi
    Sarwanti
    Fauziah, Siti
    ACTA MEDICA INDONESIANA, 2023, 55 (04) : 465 - 474
  • [44] Clinical predictors for emesis in breast cancer patients receiving anthracycline-based chemotherapy: Do Asians measure up?
    Chan, A.
    Shih, V.
    Yap, K. Y.
    Tan, S.
    Low, X.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [45] Incidence of febrile neutropenia among early-stage breast cancer patients receiving anthracycline-based chemotherapy
    Chan, Alexandre
    Chen, Christy
    Chiang, Joen
    Tan, Sze Huey
    Ng, Raymond
    SUPPORTIVE CARE IN CANCER, 2012, 20 (07) : 1525 - 1532
  • [46] Incidence of reversible amenorrhea in women with breast cancer undergoing adjuvant anthracycline-based chemotherapy with or without docetaxel
    Berliere, Martine
    Dalenc, Florence
    Malingret, Nathalie
    Vindevogel, Anita
    Piette, Philippe
    Roche, Henry
    Donnez, Jacques
    Symann, Michel
    Kerger, Joseph
    Machiels, Jean-Pascal
    BMC CANCER, 2008, 8 (1)
  • [47] Incidence of reversible amenorrhea in women with breast cancer undergoing adjuvant anthracycline-based chemotherapy with or without docetaxel
    Martine Berliere
    Florence Dalenc
    Nathalie Malingret
    Anita Vindevogel
    Philippe Piette
    Henry Roche
    Jacques Donnez
    Michel Symann
    Joseph Kerger
    Jean-Pascal Machiels
    BMC Cancer, 8
  • [48] Effect of primary anthracycline-based chemotherapy on disseminated tumor cells in locally advanced breast cancer
    Jäger, C
    Kafka, A
    Bossert, S
    Grundmann, R
    Windisch, J
    Kreienberg, R
    Heilmann, V
    ANTICANCER RESEARCH, 2004, 24 (5B) : 3209 - 3214
  • [49] Is anthracycline-based chemotherapy alone adequate for young women with estrogen receptor-positive breast cancer?
    Papaldo, Paola
    Di Cosimo, Serena
    Ferretti, Gianluigi
    Carlini, Paolo
    Fabi, Alessandra
    Cecere, Fabiana
    Cognetti, Francesco
    BREAST, 2006, 15 (02): : 269 - 272
  • [50] Cardioprotective effect of Platycodon grandiflorum in patients with early breast cancer receiving anthracycline-based chemotherapy: study protocol for a randomized controlled trial
    Wei Hao
    Sheng Liu
    Yuenong Qin
    Chenping Sun
    Liying Chen
    Chunyu Wu
    Yijia Bao
    Trials, 18